Reuters logo
BRIEF-Thrombogenics Discontinues Patient Recruitment In Its Phase II CIRCLE Study
December 8, 2017 / 6:46 AM / 6 days ago

BRIEF-Thrombogenics Discontinues Patient Recruitment In Its Phase II CIRCLE Study

Dec 8 (Reuters) - THROMBOGENICS NV:

* PATIENT ENROLMENT IN PHASE II CIRCLE STUDY EVALUATING THR-409 (OCRIPLASMIN) FOR NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) DISCONTINUED DUE TO SLOW RECRUITMENT RATE

* DECISION IS EFFECTIVE IMMEDIATELY

* DATA FROM STUDY WILL BE ANALYZED AND SHARED WITH SCIENTIFIC COMMUNITY VIA A PUBLICATION IN LATE 2018/EARLY 2019

* THROMBOGENICS WILL FOLLOW-UP WITH EVERY PATIENT INCLUDED IN STUDY, AS APPROPRIATE

* RESOURCES EARMARKED FOR CIRCLE STUDY TO BE RE-ALLOCATED TO PROGRESS NEW DRUG CANDIDATES CURRENTLY BEING EXPLORED INTO CLINIC IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below